Transcept Pharmaceuticals Inc 4
4 · Transcept Pharmaceuticals Inc · Filed Oct 30, 2014
Insider Transaction Report
Form 4
KILEY THOMAS
Director
Transactions
- Disposition to Issuer
Stock option (right to buy)
2014-10-30−1,125→ 0 totalExercise: $48.84Exp: 2023-01-07→ Common Stock (1,125 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-10-30−833→ 0 totalExercise: $38.04Exp: 2019-01-30→ Common Stock (833 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-10-30−158→ 0 totalExercise: $80.88Exp: 2020-02-03→ Common Stock (158 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-10-30−583→ 0 totalExercise: $90.24Exp: 2021-01-27→ Common Stock (583 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-10-30−583→ 0 totalExercise: $82.20Exp: 2022-01-24→ Common Stock (583 underlying) - Disposition to Issuer
Stock option (right to buy)
2014-10-30−333→ 0 totalExercise: $82.56Exp: 2020-01-14→ Common Stock (333 underlying)
Holdings
- 5,597(indirect: See footnote)
Common stock
- 2,638
Common stock
Footnotes (5)
- [F1]Number of shares accounts for the effect of a reverse stock split of Issuer's common stock at a ratio of one new share for every twelve shares outstanding effective just prior to the effective time of the merger of Paratek Pharmaceuticals, Inc. into a wholly owned subsidiary of the Issuer (the "Merger") pursuant to that certain Agreement and Plan of Merger and Reorganization ("Merger Agreement") by and among Issuer, Tigris Merger Sub, Inc., Tigris Acquisition Sub, LLC, and Paratek,Pharmaceuticals, Inc. ("Paratek") dated June 30, 2014 (the "stock split").
- [F2]Shares held directly by the Kiley Family Revocable Trust (the"Family Trust") for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the Family Trust except to the extent of his pecuniary interest therein.
- [F3]Represents the adjusted stock option exercise price reflecting the Stock Split.
- [F4]Fully exercisable.
- [F5]Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, certain outstanding options to purchase Issuer's common stock, whether vested or unvested, with an exercise price higher than the Issuer Closing Price (as defined therein), which is $21.588, were cancelled.